Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter
Date:11/24/2008

DETROIT, Nov. 24 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Alternext US: CPD) announced today that it has timely submitted its response to the FDA warning letter that was received on October 31, 2008. In the warning letter, the FDA requested a response from Caraco within 15 business days, ending November 24, 2008.

As previously disclosed, the warning letter was issued as a follow up to the last FDA inspection of the Company's manufacturing facility in Detroit, Michigan which was initiated in May 2008. Until the Company's responses to the observations have been clarified and explanations provided to the satisfaction of the FDA, the FDA may in the near term withhold approval of pending new drug applications listing the facility as the manufacturer. The Company's sales of current products continue in the normal course of business.

The Company is committed to working cooperatively and expeditiously with the FDA to resolve the matters indicated in its letter. The Company has requested a meeting with the FDA as a follow up to its response. Caraco believes it has addressed the concerns in the warning letter appropriately.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter
2. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
3. Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
4. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
6. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
7. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
8. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
9. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
10. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Chicago, Ill., and Waycross, Ga. (PRWEB) , ... ... ... a market leader and trusted advisor within the telehealth industry, announces the company’s ... with U.S. board-certified primary care providers. Available 24 hours a day, Quick Care ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the ... 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish ... course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. ...
(Date:4/24/2017)... ... 24, 2017 , ... “Reflections of God’s Work”: an enlightening collection of life ... the creation of published author, Jerri Broglin, a survivor of great loss who gained ... a great eye-opener for those searching for answers, as we are finding the answers ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is proud to ... will be held at 7:30 pm on May 10th at the University Auditorium. , ... Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert will kick ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... EAST HANOVER, N.J. , April 19, 2017 ... study conducted by the National Heart, Lung, and ... Health (NIH) demonstrating that 58% of patients with ... at six months when treated with eltrombopag at ... treatment 1 . The study evaluated three sequential ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
(Date:4/18/2017)... Viverae ® , a leader in workplace wellness technology, ... Watson Campaign Automation, implementing behavioral messaging within the ... experience. Through digital engagement, the platform prompts members to ... The enhanced experience drives engagement by focusing on the ... in their journey to health. Unlike ...
Breaking Medicine Technology: